Similarly, while the VEGF inhibitor bevacizumab has shown promise in reducing tumour cell proliferation and improving hearing in a subset of patients [10], and our lab has previously shown that patients with SH3PDX2A-HTRA1 fusion positive tumours may respond to inhibition of the MEK-ERK pathway [8], there remain an absence of medical treatments in their standard care. This evidence concerns the gene VEGFA and neoplasm.